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Summary.-Adriamycin (ADR) accumulates in well-perfused organs in the rat.
This effect is especially evident for long periods in marrow and spleen of healthy
animals. In rats bearing the Brown Norway Acute Myeloid Leukaemia (BNML)
the in vivo distribution is significantly different. Maximum ADR levels in those organs
which are morphologically infiltrated by leukaemic cells are significantly lower than
in normal rats, while the persistence of measurable ADR concentrations does not
change. On the contrary, ADR concentrations in organs not infiltrated by leukaemic
cells are the same or slightly higher than in normal rats. Possible causes for these
differences are either the differential properties ofnormal and leukaemic cells in their
uptake and excretion of ADR, or anatomical and vascular changes. It is evident that,
where leukaemia is involved, the relative distribution between serum and tissue is
significantly different from normal. This observation may help in the prevention of
toxicity by drug monitoring in serum.
THE ANTHRAQUINONE GLYCOSIDE ADRI-
AMYCIN (ADR) is ofwidespread use in the
treatment of solid tumours and acute
leukaemia (Carter, 1975). Several studies
on the distribution of the drug have
revealed its rapid clearance from plasma,
selective accumulation in various organs
and slow elimination via urinary and
biliary pathways in the rat, monkey and
man (Chan et al., 1978; Wilkinson et al.,
1979). Little information is available on
the comparative distribution kinetics of
ADR between normal tissues and malig-
nant tumours in vivo. In mice and rats
bearing solid tumours, it has been ob-
served that ADR concentrations in meta-
stases were higher than those in the parent
tumours (Donelli et al., 1977; Donelli &
Garattini, 1977), while the drug penetrates
less extensively into solid tumours than
into most normal tissues (DiFronzo et al.,
1973). However, in acute leukaemia, a
widely disseminated malignant disease,
tumour cells are present in many organs
in varying numbers. The differential drug
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uptake (Sonneveld & Van den Engh, 1981.)
and sensitivity (Buick et al., 1979; Sonne-
veld et al., 1981) between leukaemic and
normal cells observed in vitro may thus
very well influence the amount of drug
taken up in vivo by an organ, especially if
it is infiltrated by a large number of
leukaemic cells. In view of the clinically
observed variations in drug response
among acute-leukaemia patients, the
different drug uptake ofnormal and malig-
nant cells, as well as the number of leuk-
aemic cells, may be relevant factors in the
in vivo distribution of ADR. The present
study was initiated to investigate whether
the distribution kinetics of ADR differ
between normal and leukaemia-bearing
rats using an experimental leukaemia
model which has been proved to resemble
closely acute myeloid leukaemia in man,
and is highly sensitive to the antitumour
activity ofADR.
MATERIALS AND METHODS
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Leukaemia (BNML) was chosen as a model.
This acute myelocytic leukaemia originated
in 1971 in a female rat of the inbred Brown
Normway rat strain in the Rijswijk colony
(BN/Rij) following 3 i.v. injections of 2 mg
of9.10-dimethyl 1,2-benzanthracene 100 days
earlier. The leukaemia has since been main-
tained by transplantation of leukaemic cells
directly or by cryopreserved batches. The
eharacteristics of BNML have been described
cxtensively (Hagenbeek, 1977) and can be
summarized as follows:
(1) the net growth rate is slow;
(2) it is cytochemically and cytologically
identical to human acute myeloid (promyelo-
cytic) leukaemia (AML);
(3) its response to antileukaemic chemo-
therapy is similar to that of AML;
(4) the mean survival time after i.v. inoeu-
lation of 107 leukaemic spleen cells is 22 days;
(5) 2 single administrations of ADR (7 5
mg/kg, interval 7 days) increase the survival
time by 14 days.
These characteristics have made BNML a
particularly suitable model for the study of
the proliferation kinetics and experimental
treatment of acute leukaemia (Aglietta &
Colly, 1979; Aglietta & Sonneveld, 1978).
Therefore, the distribution kinetics of ADR
were investigated in normal and BNML rats,
the latter at a stage comparable with that of
human AML patients at clinical admission
(Day 15 after i.v. transplantation of 107
leukaemic spleen cells). At this stage, mar-
row, spleen and liver are heavily infiltrated
by leukaemic cells, and baemopoiesis is
severely suppressed.
Leukaemia transfer.-The leukaemic spleen
wk,as always used as a source ofleukaemic cells
for transplantation. After resuspension of
spleen cells obtained from a 21-day-old
leukaemic rat in Hanks' balanced salt solu-
tion. the required number of cells was in-
jected i.v. into a tail vein of the recipient in
a final volume of 1 ml.
Distribution studies in leukaemic rats were
generally performed at Day 15 after inocula-
tion of 107 leukaemic spleen cells.
Animnals.-The studies were performed in
the inbred BN rat strain from the Rijswijk
colony. Female rats 12 weeks of age, bred
under specific-pathogen-free (SPF) condi-
tions, were used. Water and food were always
supplied ad libitum during the experiments.
Experimental drug.-Adriamycin hydro-
chloride was kindly supplied by Farmitalia.
Milan, Italy. The chemical purity was
assessed by thin-layer chromatography, using
Merck silica-gel glass discs. The solvent used
was n-butanol, 60%; glacial acetic acid, 15%
distilled water, 25%.
The chemical purity of the drug was 9500.
No variations in purity were noted during dry
storage of the drug at room temperature.
Collection ofbiological specimens.-In most
experiments, ADR was administered into a
tail vein at a dose of 7-5 mg/kg (44 mg/M2 of
body surface) (Freireich, 1966) after solution
in sterile 0.9%0 NaCl at a final concentration
of2 mg/ml. To avoid a decrease in activity of
the drug, it was always dissolved 2 h before
each experiment.
To determine the concentrations in serum
and organs, animals were killed at various
intervals after i.v. administration ofthe drug.
For each time interval, 4 normal, 4 leukaemic
and 1 untreated animal were used. Animals
were killed by ether anaesthesia and cervical
dislocation. Blood was then obtained by
aortic puncture. The blood (generally 4 ml)
was centrifuged for 10 min at 400 g. After
carefully pipetting off the upper phase,
serum was kept at 4°C until chemical analysis
was performed. Liver, spleen, kidneys, heart
and lungs were removed from the body, weighed and homogenized immediately after
addition ofsterile 0.9% NaCl to obtain a final
dilution of 10% v/v. Immediately after
homogenization,thetissuesampleswerestored
at 4°C. Marrow was obtained after the femurs
had been freed of adherent muscle tissue:
the proximal ends were cut with a surgical
knife and the femoral shafts were emptied by
repeated flushing with Hanks' solution using
a needle on a 5ml syringe. The collected
marrow was filtered and cells were counted
microscopically using a Buirker type haema-
cytometer after staining with Tiirck's solu-
tion (001%).
Extraction procedure.-For deproteinizing
the cell suspensions and extraction of ADR
from serum and cell suspensions, the method
described by Schwartz was used, because of
its high tissue recovery (90%0) of ADR
(Schwartz, 1973). This method does not give rise to unwanted metabolism of the parent
drug during the extraction.
Determination of the ADR concentration
was performed spectrofluorometrically in a
Hitachi-FL 204 fluorescence spectrophoto-
meter. As a standard, samples from untreated
animals were used and this background
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fluorescence wvas subtracted from experi-
mental values.
In all experiments, the excitation wvave-
length wA-as 460 nm and the samples wvere read
at a fluorescence of 580 nm. Pure isoamyl
alcohol served as the blank control.
Renal function. Since Adriamycin is
partly excreted in the urine, it is necessary to
monitor renal function in experiments on the
pharmacokinetics of the drug. The creatinine
concentration of the blood, being a function
of the renal excretory capacity, *was ascer-
tained in normal and in leukaemic rats at
differeint stages of the disease. A standard
commercial kit (Boehringer, Ingelheim) was
used for spectrometric determinations.
Serumz volume. The serum volume wAas
determined by injection of 14C-inulin (sp.
act. 1-3 ,uCi/mg inulin-carboxylic acid) at a
final concentration of 10 tCi in 1 ml. After
1 min, cardiac puncture was performed and
the blood obtained was centrifuged, after
clotting, at 700 g for 10 min. The serum was
pipetted off and the radioactivity, expressed
as c/min, Xwas measured in scintillation vials
(Packard Instr., Zurich, SwAitzerland) in a
liquid scintillation counter (Nuclear Chicago,
Mark TI) using a toluene-based scintillation
fluid (50 mg POPOP and 4 g PPO/1 toluene).
The serum volume was calculated by dividing
the ct/min produced by 10 ,Ci 14C-inulin by
that produced by 1 ml of serum. The total
blood volume as derived from this value by
multiplying the serum volume by the re-
ciprocal of the baematocrit.
RESULTS
Distribution of ADR in normal and
leukaemnic rats
Although the concentration-time curve
in serum provides information on the
extent ofdrug penetration into the tissues,
selective accumulation can only be de-
tected by measuring the drug concentra-
tion in various organs. Since a leukaemia
model was chosen to study the distribu-
tion of ADR in the presence of tumour
load, the following organs were selected
for examination; liver, spleen and femoral
marrow (as major sites of leukaemic in-
filtration), heart and lungs (as major sites
for selective toxicity) and kidneys, because
of their excretory function. Figs 1-3 and
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Fia. 2. Spleen concentration of Adriamycin
in normal (-- ) andl 15-(lay leukaermic
(- -) rats following 7-5 mg/kg i.v-. (± 2
s.e.). The symbols represent the coneentra-
tion per g of tissutle.
Table II show the typical disappearance
curves obtained after i.v. administration
of 7*5 mg/kg in normal and in leukaemic
rats at Day 15 after inoculation. At this
stage, the mean weights of the organs
investigated averaged the values indicated
in Table I.
Serum (Fig. l). After i.v. administra-
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TABLE I. Weights (g) of body and organs
of normal and 15-day BNML rats
BN BNAIL
Body weiglht 165-05 + 3-10 165-85 + 4-55
Plasma 5-70+0-18 5 10+0 18
Spleen 0-35+±011 1-28+0-10
Livel 4-94+ 0-25 8-50+ 0-38
Heart 0 60 + 0-04 0-58 + 0-02
Ltungs 1-35 + 0-02 1-38 + 0 03
Kidneys 0-96+0 01 1-04+0-02
Skeleton 10-40 + 0 24
Skin :3500+ 1-45
Tlie results represent tie values (+s.cd.) obtainel
in , 60 females of 12 weeks of age. (Values for the
plasma volumes from Hagenbeek, 1977.)
tion a rapid initial decrease of the serum
concentration of ADR can be seen in both
normal and leukaemic rats followed by a
long excretory phase. These concentra-
tion-time curves suggest extensive ac-
cumulation of the drug in the tissues.
The values for leukaemic animals are con-
sistently higher than those for normal
rats. The observed differences are signifi-
cant for a number of points.
Spleen (Fig. 2). ADR levels in the
spleen reach values 1Ox the serum con-
centration within 10 min of drug adminis-
tration. Despite the initial decrease in the
first 30 min, the spleen drug levels remain
high for 24 h in normal rats. In leukaemic
animals, in which the spleen weight has
increased 5-fold and large numbers of
leukaemic cells have infiltrated the organ,
the drug levels are generally lower by a
factor 1-5-2 (in the first 24 h) than those
ofnormal rats.
i~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~~~I I
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Marrow (Fig. 3).-Considerable concen-
trations of ADR are found in the femoral
bone marrow of both normal and leu-
kaemic rats. In Fig. 3 the concentration-
time curves are plotted of the first 8 h
expressed as [kg/108 nucleated cells.
Assuming a specific density of 1-00 and a
mean cell diameter of 8 um, the weight of
108 cells is 26 mg. This means that for
comparative purpose the marrow concen-
trations ofADR may be expressed as ,ug/g
of tissue by multiplying the concentra-
tions per 108 cells by a factor of 38-5.
The concentration-time curve of ADR
in marrow is characterized by a gradual
increase both in normal and leukaemic
rats. However, in BNML rats the large
presence of leukaemic cells apparently in-
hibits drug accumulation. In BN and
BNML animals the observed peak concen-
trations in marrow are considerably
higher than in the other organs investi-
gated in this study.
Other organs.-Table II shows the dis-
appearance of ADR in several organs
which, as judged by microscopy, are
hardly if at all infiltrated by leukaemic
cells, such as lungs, heart, kidneys and
liver. Except in liver, no significant
differences can be seen between the con-
centration-time relationships in organs
from normal and leukaemic organs. The
disappearance of ADR from the liver
BN
0 BNML
Fic. 3. Concentration of Adriamyciin in
femoral marrow cells of normal ( ) and
15-day leukaemie (- - -) rats following
7-5 mg/kg i.v. (+ 2 s.e.).
iFl "
FIG. 4. Cumulative turinary excretion of
Adriamycin followkving a single i.v. boltis
injection of 7-5 mg/kg (± 2 s.e.) in normal
an(d BNML Irats.
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TABLE II.-Disappearance of ADRfrom organs of normal (BN) and leukaernic (BNML)
rats following 7-5 mg/kg i.v. (,ug/g tissue)
3NAML BN
14-0 16-7
13-5 14-6
13-9 19-1
10-5 15-5
9-5 13-1
7-9) 10-2
8-1 8-5
7-0 8-7
5-1 8-6
Lungs
BNAIL
20-0
17-1
16-9
14-7
12-7
9-8
10-8
10-3
8-9
TKidnle,s I y
BN BNAIL
:38 7 :346
26-8 28-1
29:3 24-8
2:15 20 6
219() 19-4
149 175
132 17-2
12-2 14-1
12-7 12:3
seems to be slower in leukaemic than in
normal rats.
Renal elimination
To determine the renal elimination of
ADR, rats were caged in metabolic cages,
in which urine is collected without the
chance of pollution by faeces (Hagenbeek,
1977). Fig. 4 shows the cumulative renal
elimination of ADR over 72 h in normal
animals. The mean volume of urine in
which this amount of ADR was excreted
was 21 ml. The renal function as measured
by the creatinine content of the serum
changed significantly during progress of
the disease, and was actually higher by a
factor of 1-4 at Day 15 after inoculation
ofthe leukaemia, than in healthy controls.
Biliary excretion
To determine the excretion of ADR in
bile, 9 animals were anaesthetized with
ketamine HCL and a teflon drain with a
diameter of 1 mm was inserted into the
w/
,/
/
biliary duct. The drain was led through
the cutis and inserted into a 5ml tube.
Saline (O*9%0) was administered i.v. at a
rate of 2 ml/h by an infusion pump during
sampling in order to maintain the fluid
balance. After the end of the anaesthesia,
ADR was administered i.v. in a single
dose and the bile was collected at regular
intervals. In Fig. 5, the cumulative
biliary elimination is plotted for 24 h. A
rapid initial excretion can be observed for
6 h, after which the elimination dimin-
ishes. These observations are from healthy
rats only, since leukaemic rats did not
survive the surgery.
Metabolism
Using the described TLC chromato-
graphic procedure in the first 24 h after
administration ofthe drug, no Adriamycin
or Adriamycinone could be demonstrated
in serum and urine of either normal or
leukaemic animals. This finding accords
with the results of Wilkinson et al. (1979),
who found no metabolic breakdown of
ADR in rats, using high-performance
liquid chromatography.
DISCUSSION
It is not possible to ascertain from the
serum curve which organs excessively
accumulate ADR. Careful analysis of the
distribution of the agent in several organs
is therefore needed in order to discover
where ADR accumulates and how long it
i-emains in each organ.
Analysis of the serum disappearance
curve after 7-5 mg/kg i.v. reveals that,
Heart
10 min
20 min
30 min
1II
2 I
41
8 h
12 h
24 li
BN
32-0
28-I
19-2
15-6
12-0
6-0
6-1
4-2
3-9
Liv-er
BNAML
29-2
27-5
18-8
11-4
9.7
8-4
7-8
6-1
5-2
BN I
13-9
12-7
14-5
12-8
10-6
8-9
6-1
5.9
6-2
G 6 2 IF.
F'IG. 5. Cumulative biliairy excretion of'
Adriamycin in normal rats following
7-5 mg/kg. Ttie values represent the means
of 9 animals (+ ±2 s.e.).
I
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after 10 min, the concentration is 141
,ug/ml. Bearing in mind that a total of
1240 Hg was injected into a rat of 165 g,
and that the serum volume amounts to
5*7 ml, the conclusion is that ADR is
redistributed very rapidly to the tissues.
Calculated per g of tissue, a great part of
the administered dose accumulates in the
marrow cells of both BNML and normal
rats. In view of the severe toxicity of
ADR to the normal haemopoietic system,
which is located in the marrow, this
toxicity is not only due to the haemo-
poietic system being composed of rapidly
dividing cells, but the high concentration
over a prolonged period may also be
responsible. In leukaemic animals, the
marrow concentration is considerably
lower. Leukaemic cells, which contribute
greatly to the population of the femoral
marrow, probably take up ADR less than
do normal haemopoietic cells.
A similar phenomenon can be observed
in the spleen; during the 24h observation
period, the concentration per g of spleen
tissue is relatively constant in both normal
and 15-day leukaemic rats. However, the
concentration in leukaemic spleen is sig-
nificantly lower, but shows the same dis-
appearance pattern as the normal intra-
cellular spleen concentration of normal
spleen cells. In view of the increase in the
spleen weight from 0*35 g to 1-28 g at
Day 15, reduced availability ofADR to the
individual cells in the spleen as a result of
pathological deviations of the vascular
structure should be considered as a poss-
ible causative factor. This reduction
resembles that seen in marrow infiltrated
with large numbers of leukaemic cells.
Although the total ADR in a leukaemic
spleen is greater than in the normal
spleen, the concentration per cell is lower.
At the same time, an increase in serum
concentration can be seen during the first
8 h. A redistribution of ADR presumably
occurs when a certain number of tumour
cells is present in the body. In that case,
it is impossible to estimate the concentra-
tion of ADR in the spleen from the serum
curve, since there is no information on the
exact relationship between these two
organs.
The liver, which increases in weight by a
factor of 1*72, shows only moderate de-
viations from the original concentration-
time curve. Other organs such as the
lungs, the heart and the kidneys show the
same disappearance curve in normal and
leukaemic animals. On histological ex-
amination, no leukaemic infiltration into
these organs can be demonstrated and no
increase in weight is observed (Hagenbeek,
1977). The quantitative differences be-
tween the serum curves of BN and
BNML rats can be attributed to the lower
drug levels in leukaemia-infiltrated organs:
spleen and marrow.
Previously, Donelli (1976) had found
reduced levels of ADR in tumour-infil-
trated mouse lungs, when compared with
normal lungs. In these animals, the
excretion of ADR occurs according to the
pathways which have been described
(Bachur, 1975; Benjamin et al., 1973,
1974). Since the contribution of an
enterohepatic recirculation is not defined,
it is uncertain how far the results can be
compared. An 8% biliary elimination in
24 h, compared with a 50%o excretion in
the faeces in 7 days, does not provide
strong evidence for the relevance of such
an enterohepatic circulation. The urinary
route is the major pathway of excretion in
the normal rat (26% in 72 h). However,
the decrease of normal renal elimination
function, as measured by the creatinine
content of peripheral blood, causes a de-
creased excretion of ADR in leukaemic
rats. This decrease in excretory function
leads to prolonged elevated levels of ADR
in all normal tissues of leukaemic rats. A
great proportion of the effective tumour-
reducing function and the toxicity to
normal tissues is probably a direct result
of this phenomenon, especially since ADR
elimination from many organs is slow.
Our results indicate significant differ-
ences in the general distribution of ADR
between normal and leukaemic animals.
These differences cannot be quantitated
merely from the serum cutrve. In both
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normal and leukaemic animals, various
organs show selective accumulation of the
drug. Itcanbeconcluded,therefore,thatan
estimation ofthe drug level at the tumour
site cannot be made without information
on the tumour load and the normal drug
distribution.
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